BioSpace News Archive

Formosa Pharmaceuticals, Inc. and AimMax Therapeutics, Inc. announce the submission of a New Drug Application to the United States Food & Drug Administration for APP13007, a novel aqueous nanosuspension formulation of the potent corticosteroid, clobetasol propionate, for the treatment of inflammation and pain following ocular surgery.

CANbridge Pharmaceuticals, Inc., a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced that it has appointed Jason West, Ph.D., to the position of Vice President, Head of Gene Therapy Research, effective immediately.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share.

Coherus BioSciences, Inc. announced that senior management will participate in the following investor conferences.

Select Medical Holdings Corporation announced results for its first quarter ended March 31, 2023, and the declaration of a cash dividend.

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced financial results for the first quarter ended March 31, 2023 and provided a business update.

In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “ Irish Takeover Rules ”), Horizon confirms that, as of the close of business on March 31, 2023, Horizon’s issued ordinary share capital is comprised of 228,576,339 ordinary shares, nominal value $0.0001 per share (the “ Ordinary Shares ”) and 40,000 deferred ordinary shares of €1.00 each.

Blueprint Medicines Corporation announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 18,300 shares of its common stock and an aggregate of 9,146 restricted stock units to eleven new employees under Blueprint Medicines’ 2020 Inducement Plan.

Extendicare Inc. reported results for the three months ended March 31, 2023.

Merrimack Pharmaceuticals, Inc. announced its first quarter 2023 financial results for the period ended March 31, 2023.